Table 4.
Macrophage-targeted immunotherapies for cancer patients
| Classification | Target | Agent | Representative clinical trials | Cancer type | Phase |
|---|---|---|---|---|---|
| Inhibiting TAM recruitment and expansion | CCL2 | Carlumab | NCT00992186 | Prostate cancer | 2 |
| Carlumab | NCT01204996 | Solid tumors | 1 | ||
| Carlumab | NCT00537368 | Solid tumors | 1 | ||
| Trabectedin | NCT03085225 | Soft-tissue sarcomas and ovarian carcinomas | 1 | ||
| CCR2 | PF-04136309 | NCT01413022 | Pancreatic neoplasms | 1 | |
| MLN1202 | NCT01015560 | Bone metastases | 2 | ||
| CSF-1 | MCS110 | NCT02435680 | TNBC | 2 | |
| NCT00757757 | Prostate cancer, Bone Metastases | 1/2 | |||
| CSF-1R | IMC-CS4 | NCT01346358 | Solid tumors | 1 | |
| AMG 820 | NCT01444404 | Solid tumors | 1 | ||
| Emactuzumab | NCT02323191 | Solid tumors | 1 | ||
| ARRY-382 | NCT02880371 | Solid tumors | 1/2 | ||
| Pexidartinib | NCT02777710 | Pancreatic and colorectal cancers | 1 | ||
| SNDX-6352 | NCT03238027 | Solid tumors | 1 | ||
| BLZ945 | NCT02829723 | Solid tumors | 1/2 | ||
| Cabiralizumab | NCT03158272 | Malignancies | 1 | ||
| PLX7486 | NCT01804530 | Solid tumors | 1 | ||
| Regulating TAM activation | CD40 | CP-870,893 | NCT02225002 | Advanced solid tumors | 1 |
| NCT01103635 | Melanoma | 1 | |||
| NCT00607048 | Neoplasms | 1 | |||
| NCT01456585 | Adenocarcinoma pancreas | 1 | |||
| RO7009789 | NCT02760797 | Neoplasms | 1 | ||
| NCT02588443 | Pancreatic cancer | 1 | |||
| NCT02665416 | Solid tumors | 1 | |||
| TLR7/8 | NKTR-262 | NCT03435640 | Solid tumors | 1 | |
| STING | ADU-S100 | NCT02675439 | Advanced solid tumors and lymphomas | 1 | |
| Targeting immune checkpoints | CD47 | Hu5F9-G4 | NCT03922477 | Acute myeloid leukemia | 1 |
| TTI-621 | NCT02663518 |
Hematologic malignancies and solid tumors |
1 | ||
| CC-90002 | NCT02641002 | Acute myeloid leukemia | 1 | ||
| LILRB2 | JTX 8064 | NCT04669899 | Solid tumors | 1/2 | |
| IO-108 | NCT05054348 | Solid tumors | 1 | ||
| TAM metabolism regulators | Glucose metabolism | 2-Deoxyglucose | NCT0063308 | Advanced cancer and hormone refractory prostate cancer | 1/2 |
| Macrophage cell therapy | Her-2 | CT-0508 | NCT04660929 | Her-2+ tumors | 1 |
| IFN-α2 | TEMFERON | NCT03866109 | Glioblastoma | 1/2 |
TNBC triple-negative breast cancer, CSF1R colony-stimulating factor 1 receptor, TLR toll-like receptor, STING stimulator of interferon genes, LILRB2 leukocyte immunoglobulin like receptor B2